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Nebivolol
The Somewhat-Different -Adrenergic Receptor Blocker
Thomas Münzel, MD, Tommaso Gori, MD, PHD
Mainz, Germany
Although its clinical use in Europe dates almost 10 years, nebivolol is a -blocker that has been only re-
cently introduced in the U.S. market. Like carvedilol, nebivolol belongs to the third generation of -blockers,
which possess direct vasodilator properties in addition to their adrenergic blocking characteristics. Nebivolol
has the highest 1-receptor affinity among -blockers and, most interestingly, it substantially improves en-
dothelial dysfunction via its strong stimulatory effects on the activity of the endothelial nitric oxide synthase
and via its antioxidative properties. Because impaired endothelial activity is attributed a major causal
role in the pathophysiology of hypertension, coronary artery disease, and congestive heart failure, the
endothelium-agonistic properties of nebivolol suggest that this drug might provide additional benefit beyond
-receptor blockade. Although lesser -blocker–related side effects have been reported in patients with
chronic obstructive pulmonary disease or impotence taking nebivolol, side effects and contraindications
overlap those of other -blockers. Clinically, this compound has been proven to have antihypertensive and
anti-ischemic effects as well as beneficial effects on hemodynamics and prognosis in patients with chronic
congestive heart failure. Further studies are now necessary to compare the benefit of nebivolol with that of
other drugs in the same class and, most importantly, its prognostic impact in patients with hypertension.
(J Am Coll Cardiol 2009;54:1491–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.066o
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febivolol (,=-[iminodimethylene]bis[6-fluoro-2-
hrommethanol]) is a third-generation -adrenergic re-
eptor blocker with vasodilator properties. Unlike those
f carvedilol, which are mediated by -adrenergic recep-
or blockade, these hemodynamic effects are in the case of
ebivolol primarily mediated by a direct stimulatory effect
n the endothelial nitric oxide synthase (eNOS).
This review focuses on the processes underlying endo-
helial dysfunction in cardiovascular disease and discusses
he mechanisms by which -blockade with nebivolol may
mprove this condition. Finally, it summarizes the clinical
ffects of nebivolol treatment in patients with arterial
ypertension and chronic congestive heart failure.
echanisms Underlying Endothelial Dysfunction
y releasing a number of different substances, the endo-
helium modulates not only the tone but also the struc-
ure and biology of blood vessels. Produced via 2-step
xidation of the amino acid L-arginine, nitric oxide (NO)
as potent antiatherosclerotic properties, and it works in
oncert with prostacyclin to inhibit platelet aggregation,
eutrophil adhesion to endothelial cells, and expression
rom II Medizinische Klinik für Kardiologie/Angiologie, Mainz, Germany. Dr.
ünzel has received research grants from Berlin Chemie and Forrest Hill and hasn
eceived honoraria for lectures.
Manuscript received April 14, 2009; accepted May 6, 2009.f inflammatory molecules. In high concentrations, NO
nhibits the proliferation of smooth muscle cells. The
ery short half-life of this highly unstable free radical is
rimarily determined by its capacity to react with other
xygen-derived free radicals like superoxide to form the
ighly reactive intermediate peroxynitrite (Fig. 1). Be-
ond this direct NO scavenging effect, superoxide and
eroxynitrite may trigger mechanisms that are opposite to
hose of NO and, in high concentrations, have cytotoxic
ffects mediated by direct oxidative damage of proteins,
ipids, and deoxyribonucleic acid (1). Therefore, tissue
uperoxide production and subsequent peroxynitrite for-
ation exert a major influence on vascular homeostasis
nd NO bioavailability in both experimental models and
uman disease.
In line with this, we recently reported evidence con-
rming a direct role of oxidative stress in cardiovascular
athophysiology, as we observed that those patients who
how evidence of vascular oxidative stress have a worse
rognosis (Fig. 2) (2). Thus, medical treatment of vas-
ular dysfunction should be aimed not only at increasing
evels of NO but also at reducing those of vascular
uperoxide and peroxynitrite. In line with this, a number
f studies have shown that substances that simply deliver
O such as organic nitrates will worsen rather than
mprove endothelial dysfunction via further peroxynitrite
ormation (3). Different therapeutic approaches therefore
eed to be sought: in the setting of endothelial dysfunc-
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Nebivolol and Nitric Oxide October 13, 2009:1491–9tion and high oxidative stress,
the ideal compound should
stimulate NO production and
simultaneously reduce oxidative
stress within vascular tissues.
In this state-of-the-art re-
view, we describe the pharma-
cokinetics of nebivolol and the
NO-stimulating and antioxi-
ant properties of this compound, and we present results
f pre-clinical and clinical studies with respect to treat-
ent of hypertension and heart failure.
ebivolol
ebivolol is a 1:1 racemic mixture of a D- and an
-isomer and is at present the only -blocker whose
tructure differs fundamentally from that derived from
ropranolol (Fig. 3). A number of mechanisms combine
o determine the hemodynamic changes induced by
ebivolol. These include a negative chronotropic effect,
nhibition of sympathetic outflow from cerebral vasomo-
or centers, inhibition of peripheral 1-adrenoceptors (4),
uppression of renin activity, and most importantly,
ecreased peripheral vascular resistances. Interestingly,
lthough nebivolol’s D-isomer appears to possess relevant
elective 1-blocking and mild vasodilatory properties,
he L-isomer determines the stimulation of eNOS and
ubsequent endothelium-dependent vasodilation (5), and
Figure 1 Mechanisms Underlying Endothelial
(Vascular) Dysfunction in Vascular Disease
An unbalanced production of nitric oxide (NO) and superoxide (O2
) leads to
inappropriate formation of peroxynitrite (ONOO). Peroxynitrite and superoxide
cause vascular dysfunction through several mechanisms (reviewed in Forster-
mann and Munzel [1]). Peroxynitrite is a strong inhibitor of NO and prostacyclin
(PGI2) signaling, and it may cause eNOS uncoupling, causing this enzyme to
produce superoxide instead of NO. ADMA  asymmetrical dimethylarginine;
cGMP  guanosine 3=,5=-cyclic monophosphate; cGK  cGMP-dependent
kinase; eNOS  endothelial nitric oxide synthase; ET  endothelin; sGC  sol-
uble guanylate cyclase; TXA  thromboxane.
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
eNOS  endothelial nitric
oxide synthase
NO  nitric oxidennly at suprapharmacologic dosages does it exert
-blocking effects (6).
These differences between isomers might well have
linical implications, and separate administration of 1 of
he 2 could be hypothesized for selected patients. In
ombination, the 2 stereoisomers of nebivolol cooperate
n determining the hemodynamic impact of the drug
6,7). The very high selectivity for 1- versus 2-
drenergic receptors of the d-isomer (Table 1) explains
he limited effects on airway reactivity and insulin sensi-
ivity (8,9) as well as the lesser negative inotropic effect of
ebivolol in patients with heart failure (10,11). Of note,
his selectivity tends to be overcome at dosages 10 mg
nd in poor metabolizers, causing the loss of this positive
haracteristic of nebivolol. Although nebivolol has no
ntrinsic sympathomimetic activity (and actually has
-blocking properties, like carvedilol), it possesses ago-
istic activity on 3-receptors, which may partially con-
ribute to explain its endotheliotropic effects (4).
lectrophysiological Properties
ike other -blockers, nebivolol has important electro-
hysiologic properties because it increases the ventricular
brillation threshold, therefore reducing ventricular ar-
hythmias in animal models of ischemia- or drug-induced
ardiomyopathy (12), and it reduces QT dispersion, a
arker of arrhythmic risk (13). Further, nebivolol reduces
-wave dispersion on the electrocardiogram, which would
ttenuate the risk of atrial fibrillation, one of the leading causes
f death in heart failure and hypertension (14).
ndothelium-Dependent Vasodilator Effects
long with its cardiac effects, the most interesting (and
ikely clinically relevant) property of nebivolol is its ability to
ause specific endothelial vasodilation, as Gao et al. (15)
emonstrated that the dose-dependent vasodilation induced
y nebivolol is abolished after the removal of endothelium
r inhibition of eNOS. Of note, other drugs in the same
lass, such as celiprolol or bopindolol, have also been shown
o exert an eNOS-stimulatory effect similar to that of the
-isomer of nebivolol (15–20). Although several mecha-
isms have been proposed for nebivolol-induced relaxations,
ncluding estrogen receptor-dependent eNOS translocation
nd phosphorylation of the serine 1177 (21) or stimulation
f serotonin receptors (16), the most attractive concepts in
his regard include activation of eNOS via binding of a
ebivolol metabolite to 2-receptor (22), direct binding of
ebivolol to the 3-receptor (23), and/or stimulation of
ndothelial adenosine triphosphate efflux (Fig. 4) (24).
In a study by Broeders et al. (22), nebivolol per se was
nable to cause vasodilation at all; however, when al-
owed to metabolize, the addition to aortic tissue in-
reased endothelial calcium concentrations and doubled
O release in a 2-receptor– dependent fashion. Immu-ohistochemistry revealed the presence of 2- but not
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October 13, 2009:1491–9 Nebivolol and Nitric Oxide1-receptors on endothelial cells. Further, in human and
odent coronary microvessels, nebivolol induces vasodila-
ion via endothelium-dependent hyperpolarization and
O (25), an effect that is abolished by eNOS inhibition,
s specifically blocked by 3-inhibitors, and is absent in
3-knockout animals (23). Finally, nebivolol stimulates
ndothelial adenosine triphosphate-efflux, increasing en-
othelial calcium levels via P2Y-receptors and determin-
ng calcium-dependent activation of the eNOS in the
enal glomerular microvasculature (24). Thus, the exact
Figure 2 Oxygen Free Radicals in Cardiovascular Pathophysiolo
(Left) Kaplan-Meier analysis demonstrating cumulative proportion of patients witho
vasodilation is divided into values below and above the median. Interestingly, pati
patients with a weak response to vitamin C. Thus, a strong vitamin C-induced imp
arteries as well. (Right) Mechanistic hypothesis: vitamin C may restore eNOS func
Details in Forstermann and Munzel (1). NOS  nitric oxide synthase; Vit  vitamin
Figure 3 Structure of Nebivolol
Compared With Other -Blockersechanism of nebivolol-induced eNOS stimulation, par-
icularly in humans, remains somewhat controversial.
uman Data
vidence of eNOS-dependent vasodilator effects of
ebivolol was also reproduced in humans in the arterial
nd venous circulation, where both direct endothelium-
ependent vasodilation and increased responsiveness to
ther specific stimuli such as hyperemia were reported
26 –28). Remarkably, the magnitude of this effect was
imilar across hypertensive patients and healthy volun-
eers (Fig. 5), which shows that the presence of vascular
isease does not limit the endothelium-dependent vaso-
ilator capacity—and hemodynamic benefit—achievable
harmacologically. Of note, similar data also were repro-
uced with celiprolol, which has been shown to cause
irect coronary vasodilation (29). In a double-blind
andomized study in hypertensive patients, Tzemos et al.
30) demonstrated that, despite having blood pressure-
owering effects comparable with those of atenolol,
ebivolol therapy was associated with a highly significant
mprovement of NO-mediated endothelial function
Fig. 5). In line with these data, beneficial effects of
diovascular events during follow-up. Effect of vitamin C on acetylcholine-induced
ho responded well to vitamin C treatment had a worse prognosis compared with
nt of endothelial dysfunction may point to increased oxidative stress in coronary
y either direct scavenging of superoxide (red) or by recoupling of the eNOS.
r abbreviations as in Figure 1.
ifferential Selectivity of-Blockers for -Receptor SubtypesTable 1 Differen ial Selectivity of
-Blockers for -Receptor Subtypes
Compound 1/2 Selectivity Additional Effect
Propranolol 1
Metoprolol 74
Bisoprolol 103
Celiprolol 69 2 agonism (lungs, endothelium)
Carvedilol 1 1-blockade, antioxidantgy
ut car
ents w
roveme
tion b
; otheNebivolol 321 2-3 agonism (endothelium)
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Nebivolol and Nitric Oxide October 13, 2009:1491–9ebivolol treatment have been demonstrated in smokers
31) as well as in patients with hypertension (32) or
oronary artery disease (33). Of note, the observation that
he L- and the d-isomer of the drug possess different
roperties suggests that they could be separately admin-
stered to patients who can benefit from one more than
he other.
ebivolol Reverses Endothelial
ysfunction in Animal Models of Oxidative Stress
s mentioned previously, an important determinant of
he half-life of NO is the simultaneous production of
eactive oxygen species in vascular endothelial and
mooth muscle cells. Improvement of endothelial (vascu-
ar) dysfunction in vivo may thus be secondary to inhi-
ition of superoxide-producing enzymes such as the
icotinamidediphosphate [NAD(P)H] oxidase, mito-
hondria, or the cyclooxygenase, or to recoupling of the
NOS (Fig. 1). We recently demonstrated that nebivolol,
ut not other -blockers, improves endothelial function,
educes vascular superoxide production via prevention of
NOS uncoupling, reduces vascular macrophage infiltra-
ion, and inhibits NAD(P)H oxidase-dependent super-
xide production in neutrophils isolated from hyperlip-
demic rabbits (Fig. 5) (34). Similarly, in a model of
ngiotensin II-induced oxidative stress (35), we observed
hat nebivolol, but not metoprolol, normalizes endothe-
ial function, reduces superoxide formation, increases NO
ioavailability, and inhibits up-regulation of the activity
nd expression of the vascular NAD(P)H oxidase (35),
Figure 4 Mechanisms Underlying Release of NO
in Response to Acute Nebivolol Challenges
In renal glomeruli, nebivolol activates mechanosensitive ion channels, which sub-
sequently release adenosine triphosphate (ATP) and stimulate P2Y receptors,
causing calcium-dependent eNOS activation (24). Nebivolol or its metabolite may
also activate 2 (in conduit arteries) (22) or 3-receptors (in resistance arteries)
(23), which also increase intracellular calcium, thereby activating eNOS. cAMP 
cyclic adenosine monophosphate; cGMP  cyclic guanosine monophosphate;
ER  estrogen receptor beta; other abbreviations as in Figure 1.hus preventing eNOS uncoupling. cThe effects of nebivolol on endothelial NO, superoxide
nd peroxynitrite release were studied in human umbilical
ein endothelial cells and iliac artery endothelial cells
solated from age-matched black and white Americans
36). The rate of NO release was 5 times slower in black
han in white subjects, whereas the rates of release were
times faster for superoxide and 4 times faster for
eroxynitrite. Pre-treatment with nebivolol restored NO
ioavailability in endothelial cells from black donors with
oncurrent reductions in superoxide and peroxynitrite,
imilar to levels in the endothelium of white subjects.
he effects of nebivolol were clearly dose dependent and
ot observed with atenolol. In addition, similar effects
ere observed with apocynin, an NAD(P)H oxidase
nhibitor (36), suggesting that NAD(P)H oxidase activa-
ion may subsequently trigger eNOS uncoupling (Fig. 6)
s demonstrated by our animal experiments (34,35).
Finally, nebivolol treatment has been demonstrated to
nhibit the oxidized low-density lipoprotein-induced in-
ctivation of NO (37) and to reduce the levels of the
irculating eNOS inhibitor asymmetric dimethyl-
rginine, which likely contributes to increase vascular NO
ioavailability (38).
latelet Aggregation and Thrombus Formation
n vitro, nebivolol, propranolol, and carvedilol have all
een shown to inhibit both adenosine diphosphate- and
ollagen-induced platelet aggregation; however, the effect
f nebivolol appears to be significantly greater, and it is
ost after inhibition of eNOS (39). Further, therapy with
ebivolol causes a significant decrease in mean platelet
olume and plasma sP-selectin levels and is associated
ith favorable modifications of hemostatic and fibrino-
ytic status (40,41), including reduced plasma levels of
brinogen plasma activator inhibitor-1, homocysteine,
nd endothelin-1 (41,42).
ntiproliferative Effects
ebivolol causes down-regulation of a number of genes
nvolved in inflammatory processes, oxidative stress, and
mooth muscle cell proliferation (43– 46). Such antipro-
iferative and proapoptotic effects have obvious potential
mplications in the prevention and treatment of athero-
clerosis. Of interest, this antiproliferative action (along
ith that of other NO donors), although being NO-
ediated, appears to be independent of cyclic guanosine
onophosphate (47). In agreement with these findings,
ebivolol has been shown to inhibit the expression of
nflammatory proteins and factors involved in vascular
emodeling such as metalloproteinases and protease in-
ibitor (44,45,48). In hyperlipidemic animals, augmen-
ation of NO with nebivolol increased plaque stability
40). Further, nebivolol inhibited neointima formation in
murine model of vascular injury (45), and it preventedardiac and renal modifications in a rat model of insulin
r
m
C
T
d
h
n
H
p
t
w
h
(
s
s
l
C
a
t
o
b
I
a
c
a
t
h
i
d
a
w
h
u
u
r
H
a
r
3
m
a
h
1495JACC Vol. 54, No. 16, 2009 Münzel and Gori
October 13, 2009:1491–9 Nebivolol and Nitric Oxideesistance (49). Finally, nebivolol inhibited the develop-
ent of atherosclerosis in cholesterol-fed rats (50).
linical Trials
he primary indications for which nebivolol has been
eveloped and studied include systemic hypertension,
eart failure, and although less data are available, coro-
ary artery disease.
ypertension. A number of randomized, double-blind,
lacebo-controlled trials have investigated the efficacy and
olerability of 5 to 10 mg of nebivolol therapy in patients
ith mild-to-moderate essential hypertension. Nebivolol
as a relatively modest impact on diastolic blood pressure
51), a characteristic that is believed to contribute to the
afety profile of the drug. In terms of effectiveness on
ystolic blood pressure, studies (52–54) suggest that nebivo-
ol compares at the same level with other -blockers and
a2-antagonists and is somewhat more potent than
ngiotensin-converting enzyme (ACE) inhibitors (54). The
ypical onset of maximal nebivolol antihypertensive effect
ccurs after 2 to 8 weeks of therapy, which is intermediate
Figure 5 Impact of Nebivolol on Endothelial Responses and Fre
Effects of intra-arterial infusion of nebivolol on forearm blood flow in healthy contro
nebivolol but not atenolol caused vasodilation, an effect that was antagonized by
flow in response to the endothelium-dependent vasodilator acetylcholine after trea
thelial function in hypertensive patients (30). (D) Nebivolol, but not other -blocke
hypercholesterolemic rabbits (34). EPR  electron paramagnetic resonance.etween ACE inhibitors (slower) and amlodipine (faster). mn recent meta-analyses (55), the percentage of patients who
chieved target blood pressure levels was somewhat greater
ompared with ACE inhibitors and comparable with
ngiotensin-II blockers or Ca2-channel antagonists. Al-
hough these preliminary observations appear promising, it
as to be emphasized that outcome data from large studies
n isolated hypertension are currently not available and will
efinitely have to be gathered in the next years, particularly
fter the recent observations of neutral or comparatively
orse effects of -blockers on mortality and morbidity in
ypertension (56). In the absence of such data (and partic-
larly of a comparison of nebivolol with other drugs), the
se of any -blocker as a first-line agent in hypertension
emains under discussion.
eart failure. Large randomized trials and meta-
nalyses (57) have shown that -blocker administration
educes 5-year mortality and morbidity by approximately
0% in heart failure patients by reducing adrenergic drive,
odulating sympathovagal balance and rate variability,
nd improving cardiac performance. -blocker therapy,
owever, is not deprived of side effects in these patients,
dicals Production
ects (A) and patients with essential hypertension (B) (26,27). In both groups,
elial nitric oxide synthase (eNOS) inhibition. (C) Percent change in forearm blood
with atenolol or nebivolol, respectively. Nebivolol alone markedly improved endo-
ibits phorbolester (PDBu)-induced superoxide production in neutrophils frome Ra
l subj
endoth
tment
rs, inhostly because of the negative inotropic and chrono-
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Nebivolol and Nitric Oxide October 13, 2009:1491–9ropic effects of these drugs. Importantly, although other
-blockers mostly act by reducing stroke volume, nebivo-
ol and carvedilol preserve left ventricular function, cause
eripheral vasodilation, maintain stroke volume and car-
iac output, and preserve cardiac chronotropism during
xertion (58 – 61). Further, compared to bisoprolol, they
o not cause the increase in (or actually improve) (62)
ulmonary artery and wedge pressure (63). Whether
hese differences will translate in a more favorable out-
ome remains to be studied.
A shortcoming of -blocker studies in heart failure is that
hey have enrolled subjects younger than the real-world heart
ailure population. The mean age of patients included in these
revious trials was in the range of 60 years, and only approx-
mately 25% of the patients were older than 70 years. Al-
hough trends for benefit were reported in older and more
rail patients (64,65), these large studies were not pow-
red to detect statistical significance. More recently, the
esearchers of the SENIORS (Study of Effects of
ebivolol Intervention on Outcomes and Rehospitalization
n Seniors With Heart Failure) study enrolled heart failure
atients older than 70 years of age and showed a 14%
roportional reduction in all-cause mortality as well as an
Figure 6 Typical Tracings of the Changes in NO, O2
, and ONO
by Nanosensors From a Single Endothelial Cell Harves
Treatment with nebivolol increased NO and decreased O2
 and ONOO in cells from b
compatible with recoupling of eNOS in these endothelial cells (36). Abbreviatiomprovement in cardiac diameters and function (66) but not in bospitalization after nebivolol therapy compared with placebo
67). Although these data appear to be somewhat less favorable
han those observed in other -blocker trials, a nonpre-
pecified analysis in patients younger than 75 years of age and
ith an ejection fraction35% showed a hazard ratio of 0.62,
n line with other -blockers in other studies.
Thus, although the exact mechanism of action in heart
ailure remains unclear (reduction in ventricular wall
tress, favorable left ventricular remodeling, neurohor-
onal inhibition, protection from ischemic events),
-blockers are invaluable tools in the treatment of heart
ailure. At present, data on a favorable effect of nebivolol
xist; however, given the differences in trial designs, no
efinitive conclusion can be drawn on the comparison
ith other -blockers (selective or nonselective), and
urther comparative studies are necessary.
oronary artery disease. As reported previously, nebivo-
ol has been shown to have protective effects in experi-
ental models of experimental ischemia and reperfusion
njury (68). In humans, it was shown that administration
f nebivolol, as compared with atenolol, more effectively
mproves exercise tolerance and time to onset of angina
uring exercise test (69). Nebivolol and carvedilol have
oncentrations Recorded
rom Age-Matched White and Black Americans
atients
in Figure 1.O C
ted F
lack p
ns aseen shown to increase coronary flow reserve in patients
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October 13, 2009:1491–9 Nebivolol and Nitric Oxideith ischemic heart disease and nonischemic dilated
ardiomyopathy more consistently than other -blockers,
hich is expected to be associated with a clinically
elevant reduction in ischemic threshold (70). Data on
he mortality and morbidity impact of nebivolol in
oronary artery disease are awaited.
ide Effects
ebivolol is contraindicated in patients with severe
radycardia, atroventricular nodal block greater than first
egree, cardiogenic shock, decompensated heart failure,
nd severe hepatic disease. Warnings also have been
ssued regarding abrupt cessation of therapy, heart fail-
re, coronary syndromes, bronchospastic diseases, anes-
hesia and major surgery, diabetes and hypoglycemia,
hyrotoxicosis, peripheral vascular disease, nondihydro-
yridine calcium channel blockers use, and anaphylactic
eactions. In patients with asthma and chronic obstruc-
ive pulmonary disease, nebivolol’s greater selectivity for
1-receptors results in improved tolerability: in patients
ith mild asthma, nebivolol induced a mild, clinically
nsignificant reduction in respiratory parameters that was
ot different from that of celiprolol, a 1-blocker and
2-agonist (71,72). After a 4- and 12-week treatment on
ypertensive patients, the use of nebivolol actually in-
reased peak expiratory flow and quality-of-life parame-
ers (73).
Similarly, nebivolol appears to have a minor, if any,
ffect on libido and sexual performance, which likely
nsues from a compensatory effect of the increased NO
elease (74). In contrast with metoprolol, nebivolol im-
roves secondary sexual activity and erectile dysfunction
cores (75), a characteristic that might significantly im-
rove the compliance to this drug.
Common adverse effects reported with nebivolol in clin-
ffects of Nebivolol as Compared With the Most Commonly Used Dn the Same Class; in North America, Nebivol l Is Licensed for HypTable 2 Effects of Nebivolol as Compared With the Most Commin the Same Class; in North America, Nebivolol Is Lice
Coronary Artery Disease Heart Failure
Atenolol Less effective? (76) Benefit†
Propranolol Increased exercise tolerance Benefit
Metoprolol Increased exercise tolerance Benefit. Tartrate likely less effec
than carvedilol (77)
Carvedilol Increased exercise tolerance;
improves coronary flow
reserve‡
Benefit. Maintains cardiac index
Bisoprolol Increased exercise tolerance Benefit
Nebivolol Increased exercise tolerance;
improves coronary flow
reserve
Benefit. Comparative data not
exhaustive. Maintains cardiac
index
ata should be interpreted cautiously because direct comparative trials often are not available. *A
atients treated with all drugs listed in the table. Of these drugs, nebivolol is the only one felt to act b
-blockers in their beneficial effects in heart failure patients, except, possibly, for metoprolol tar
-blockers on coronary flow reserve is complex. Carvedilol and nebivolol show a more consistent i
O independent (39). Impact on mortality and morbidity has not been investigated.cal trials included fatigue, headache, dyspnea, insomnia,izziness, and paresthesia; however, the incidence of these
ymptoms was not different in placebo-treated subjects
0–5%) (76). Importantly, nebivolol does not appear to
odify low-density lipoprotein cholesterol or total choles-
erol levels, and it does not seem to precipitate diabetes.
ecause it is metabolized by CYP450-2P6, nebivolol is
otentiated by inhibitors of this enzyme, such as fluoxetine,
nd any coadministration should be avoided.
ummary
ebivolol is a third-generation -adrenergic receptor
locker with endothelium-dependent vasodilator properties.
vailable clinical data show an efficacy that is in line
ith that of other drugs in the same class (Table 2)
39,62,70,77–79). Nebivolol and/or its metabolites possess
irect stimulatory effects on eNOS activity as well as potent
ntioxidant properties, which may have a profound impact
n the pathophysiology and progression of cardiovascular
isease. Nebivolol has the greatest specificity for 1-
eceptors, which explains its high tolerability in patients
ith lung disease. Although a decade of clinical experience
ith this drug in Europe provides support to its blood
ressure-lowering and anti-ischemic effects, further clinical
rial data are necessary. Particularly, comparative trials on
he efficacy of nebivolol versus other -blockers and/or
ther antihypertensive drugs are awaited.
eprint requests and correspondence: Dr. Thomas Münzel, II
edizinische Klinik für Kardiologie/Angiologie, Langenbeckstrasse
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